{
  "approved_at_utc": null,
  "subreddit": "stocks",
  "selftext": "Shares of Palantir closed up more than 21% Monday after Bloomberg reported that the company won a three-year contract with the U.S. Food and Drug Administration.\n\nThe deal is worth $44.4 million and will focus on powering drug reviews and inspections, according to the report.\n\nCo-founded in 2003 by tech investors Peter Thiel and Joe Lonsdale, CEO Alex Karp and others, Palantir provides data analytics software and services to government agencies and large companies. But its government work makes up more than half of its revenue, bringing in $163 million in its latest quarter.\n\nThe company said in November recent contracts it received during the third quarter include a $91 million deal with the U.S. Army, a $36 million contract with the National Institutes of Health $36 million and a $300 million renewal with an aerospace customer.\n\nPalantir stock has surged nearly 200% since it went public Sept. 30.\n\n[Source](https://www.cnbc.com/2020/12/07/palantir-jumps-17percent-on-report-of-44-million-fda-contract.html)",
  "author_fullname": "t2_d29iz",
  "saved": false,
  "mod_reason_title": null,
  "gilded": 0,
  "clicked": false,
  "title": "Palantir closes up 21% on report of $44 million FDA contract",
  "link_flair_richtext": [],
  "subreddit_name_prefixed": "r/stocks",
  "hidden": false,
  "pwls": 6,
  "link_flair_css_class": "news",
  "downs": 0,
  "top_awarded_type": null,
  "hide_score": false,
  "name": "t3_k8pjan",
  "quarantine": false,
  "link_flair_text_color": "dark",
  "upvote_ratio": 0.96,
  "author_flair_background_color": null,
  "subreddit_type": "public",
  "ups": 446,
  "total_awards_received": 3,
  "media_embed": {},
  "author_flair_template_id": null,
  "is_original_content": false,
  "user_reports": [],
  "secure_media": null,
  "is_reddit_media_domain": false,
  "is_meta": false,
  "category": null,
  "secure_media_embed": {},
  "link_flair_text": "News",
  "can_mod_post": false,
  "score": 446,
  "approved_by": null,
  "author_premium": true,
  "thumbnail": "",
  "edited": false,
  "author_flair_css_class": null,
  "author_flair_richtext": [],
  "gildings": {
    "gid_1": 1
  },
  "content_categories": null,
  "is_self": true,
  "mod_note": null,
  "created": 1607404001,
  "link_flair_type": "text",
  "wls": 6,
  "removed_by_category": null,
  "banned_by": null,
  "author_flair_type": "text",
  "domain": "self.stocks",
  "allow_live_comments": true,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><p>Shares of Palantir closed up more than 21% Monday after Bloomberg reported that the company won a three-year contract with the U.S. Food and Drug Administration.</p>\n\n<p>The deal is worth $44.4 million and will focus on powering drug reviews and inspections, according to the report.</p>\n\n<p>Co-founded in 2003 by tech investors Peter Thiel and Joe Lonsdale, CEO Alex Karp and others, Palantir provides data analytics software and services to government agencies and large companies. But its government work makes up more than half of its revenue, bringing in $163 million in its latest quarter.</p>\n\n<p>The company said in November recent contracts it received during the third quarter include a $91 million deal with the U.S. Army, a $36 million contract with the National Institutes of Health $36 million and a $300 million renewal with an aerospace customer.</p>\n\n<p>Palantir stock has surged nearly 200% since it went public Sept. 30.</p>\n\n<p><a href=\"https://www.cnbc.com/2020/12/07/palantir-jumps-17percent-on-report-of-44-million-fda-contract.html\">Source</a></p>\n</div><!-- SC_ON -->",
  "likes": null,
  "suggested_sort": null,
  "banned_at_utc": null,
  "view_count": null,
  "archived": false,
  "no_follow": false,
  "is_crosspostable": false,
  "pinned": false,
  "over_18": false,
  "awarders": [],
  "media_only": false,
  "link_flair_template_id": "866eb162-65e6-11e5-a903-1252b640afe9",
  "can_gild": false,
  "spoiler": false,
  "locked": false,
  "author_flair_text": null,
  "treatment_tags": [],
  "visited": false,
  "removed_by": null,
  "num_reports": null,
  "distinguished": null,
  "subreddit_id": "t5_2qjfk",
  "mod_reason_by": null,
  "removal_reason": null,
  "link_flair_background_color": "",
  "id": "k8pjan",
  "is_robot_indexable": true,
  "report_reasons": null,
  "author": "Brothanogood",
  "discussion_type": null,
  "num_comments": 132,
  "send_replies": true,
  "whitelist_status": "all_ads",
  "contest_mode": false,
  "mod_reports": [],
  "author_patreon_flair": false,
  "author_flair_text_color": null,
  "permalink": "/r/stocks/comments/k8pjan/palantir_closes_up_21_on_report_of_44_million_fda/",
  "parent_whitelist_status": "all_ads",
  "stickied": false,
  "url": "https://www.reddit.com/r/stocks/comments/k8pjan/palantir_closes_up_21_on_report_of_44_million_fda/",
  "subreddit_subscribers": 967564,
  "created_utc": 1607945298,
  "num_crossposts": 0,
  "media": null,
  "is_video": false,
  "the_new_excerpt": "Shares of Palantir closed up more than 21% Monday after Bloomberg reported that\nthe company won a three-year contract with the U.S. Food and Drug\nAdministration.\n\nThe deal is worth $44.4 million and will focus on powering drug reviews and\ninspections, according to the report.\n\nCo-founded in 2003 by…",
  "original_created_utc": 1607375201,
  "localize": [
    {
      "locale": "zh",
      "the_new_excerpt": "Palantir股价周一收盘上涨逾21%，此前彭博社(Bloomberg)报道称，\n该公司赢得了与美国食品和药物管理局(U.S.Food and Drug)为期三年的合同\n行政部门。\n\n这笔交易价值4440万美元，将专注于推动药品审查和\n根据报告，检查。\n\n由…于2003年共同创立",
      "title": "据报道，FDA价值4400万美元的合同公布后，Palantir收盘上涨21%"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "Palantir股價週一收盤上漲逾21%，此前彭博社(Bloomberg)報道稱，\n該公司贏得了與美國食品和藥物管理局(U.S.Food and Drug)爲期三年的合同\n行政部門。\n\n這筆交易價值4440萬美元，將專注於推動藥品審查和\n根據報告，檢查。\n\n由…於2003年共同創立",
      "title": "據報道，FDA價值4400萬美元的合同公佈後，Palantir收盤上漲21%"
    }
  ],
  "source_updated_at": 1609260493095
}